Lattanzi S, et al. - This meta-analysis examined the efficacy and safety profile of adjunctive perampanel (PER) in patients with Parkinson’s disease (PD) by analyzing changes from baseline to final efficacy visit in total daily OFF time, activities of daily living during OFF time and motor function during ON time, incidence of adverse events (AEs), and treatment withdrawal. The PER and placebo-treated groups did not exhibit any major variations in any efficacy outcome. Moreover, findings unveiled similar risk ratios (RRs) for AEs, severe AEs and treatment withdrawal between placebo and PER at 0.5, 1 and 2 mg. The inference drawn was that adjunctive PER did not improve the motor state and was well-tolerated at the lower doses in PD patients experiencing motor fluctuations.